GA Glybera Alipogene Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. We strive to transform and simplify care for people with life threatening illnesses around the world. At GA we are inspired by the opportunity to address unmet medical needs for patients living with life-threatening diseases around the world.
Glybera Alipogene portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions.
Glybera Alipogene was founded in 1981 in Basel, Switzerland Since then, we have grown to become one of the world’s largest biopharmaceutical companies, with 8,073 employees across six continents.
Glybera Alipogene was one of the first companies to bring targeted treatments to patients. With our combined strength in pharmaceuticals and diagnostics, we are better equipped than any other company to further drive personalised healthcare. Two-thirds of our Research and Development projects are being developed with companion diagnostics As a global healthcare company, we take on some of the world’s biggest healthcare challenges.